Moreover, TGFβ, which is highly abundant in fibrotic lungs (Yue, Shan, & Lasky, 2010), plays an important role during EndMT (Piera‐Velazquez & Jimenez, 2019), and in vitro evidence indicates that VEGF, whose levels are reduced in IPF patients (Barratt, Flower, Pauling, & Millar, 2018), can block this effect (Yang, Wylie‐Sears, & Bischoff, 2008). Here, TGFB1 is linked to idiopathic pulmonary fibrosis.